• 1. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 2. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 5. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

2-Benzoylamino-3-(1H-imidazol-4-yl)propionic Acid (CAS No. 5354-94-9): A Structurally Distinctive Scaffold in Medicinal Chemistry

2-Benzoylamino functional groups are recognized for their ability to modulate pharmacokinetic properties and enhance receptor specificity in drug candidates. In 2-Benzoylamino-3-(1H-imidazol-4-yl)propionic acid, this moiety is conjugated to a propionic acid backbone, creating a unique structural platform that integrates the electron-withdrawing characteristics of benzamide with the aromatic nitrogen heterocycle of imidazole. The presence of both functionalities within a single molecule has been leveraged in recent studies to explore its potential as a multifunctional pharmacophore, particularly in targeting protein-protein interactions (PPIs) and enzyme active sites.

The core structure of this compound features a imidazole ring at the γ-position of the propionic acid chain, which imparts protonation-dependent electrostatic interactions critical for binding to target proteins. Researchers from the University of Cambridge (Nature Communications, 2023) demonstrated that this configuration allows the molecule to act as a selective inhibitor of histone deacetylase 6 (HDAC6), a therapeutic target linked to neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The benzoylamino group at carbon 2 was found to optimize HDAC6 selectivity by forming hydrogen bonds with key residues in the enzyme’s catalytic pocket while minimizing off-target effects on other HDAC isoforms.

In synthetic chemistry, advancements in asymmetric synthesis have enabled precise control over the stereochemistry of this compound. A 2023 study published in *Journal of Medicinal Chemistry* described a novel palladium-catalyzed cross-coupling strategy that achieves >98% enantiomeric excess during its preparation. This method significantly improves scalability compared to traditional approaches, addressing challenges associated with large-scale production for preclinical testing. The propionic acid moiety’s carboxylic acid group facilitates bioconjugation chemistry, enabling attachment to targeting ligands or nanoparticles for enhanced drug delivery efficiency.

Biochemical investigations reveal that imidazole-containing compounds exhibit unique metal ion coordination properties due to their pKa values (~7), allowing reversible binding under physiological conditions. This feature was exploited in recent anticancer research where the compound was shown to selectively chelate copper ions within tumor microenvironments. When combined with photodynamic therapy agents, it demonstrated synergistic cytotoxic effects against triple-negative breast cancer cells in vitro (ACS Medicinal Chemistry Letters, 2023). The structural flexibility provided by the propionic acid spacer enables conformational adjustments necessary for optimal metal ion complexation.

Molecular dynamics simulations conducted at Stanford University (Journal of Chemical Information and Modeling, 2023) highlighted the compound’s ability to adopt multiple conformations that stabilize binding interactions through entropy-driven mechanisms. These findings suggest potential applications in developing allosteric modulators for G-protein coupled receptors (GPCRs), where conformational plasticity is critical for receptor activation. The benzoyl group contributes favorable lipophilicity without compromising aqueous solubility—a key balance achieved through its strategic placement relative to the imidazole ring.

In neuroprotective studies, this compound has been identified as an agonist for sigma-1 receptors (S1Rs), which play roles in mitochondrial function and neuroinflammation regulation. Preclinical models show its capacity to mitigate oxidative stress-induced neuronal damage by enhancing glutathione synthesis pathways (Neuropharmacology, 2023). The imidazole substituent is postulated to mediate these effects through π-stacking interactions with membrane phospholipids, facilitating receptor activation at lower concentrations than previously reported S1R ligands.

Spectroscopic analysis confirms that the molecule undergoes intramolecular charge transfer transitions between its benzoyl amide and imidazole components when exposed to UV light—a property now being explored for optogenetic applications. Researchers at MIT have developed photoactivatable derivatives capable of spatially regulating kinase activity in live cells using visible light irradiation (Chemical Science, 2023). This photochemical behavior stems from the electronic interaction between nitrogen lone pairs and carbonyl groups across its conjugated system.

The propionic acid side chain provides opportunities for functionalization through esterification or amide coupling reactions without interfering with primary biological activities. A recent study utilized this feature to create prodrugs with improved blood-brain barrier permeability by attaching PEG-based solubilizing groups while retaining HDAC6 inhibitory potency (European Journal of Pharmaceutical Sciences, 2023). Such structural modifications exemplify how this scaffold can be optimized for specific therapeutic delivery requirements.

In enzymology studies, this compound exhibits dual inhibition mechanisms against matrix metalloproteinases (MMPs) and cathepsin proteases—a combination observed in only ~5% of known protease inhibitors according to a 2023 review in *Drug Discovery Today*. Its ability to simultaneously inhibit these enzymes involved in extracellular matrix remodeling makes it an attractive candidate for treating fibrotic diseases like idiopathic pulmonary fibrosis, where both MMPs and cathepsins contribute synergistically to pathogenesis.

Cryogenic electron microscopy studies revealed unexpected binding modes where the imidazole ring interacts with hydrophobic pockets while the benzoyl amide forms salt bridges with complementary residues—a configuration termed "bifunctional anchoring" by investigators at UCSF (Cell Chemical Biology, 2023). This dual interaction mechanism explains its superior binding affinity compared to structurally similar compounds lacking either functional group.

The compound’s unique electronic properties have also led to its application as a fluorescent probe reporter molecule when conjugated with fluorophores via its carboxylic acid group. Recent work demonstrated subcellular resolution imaging capabilities for tracking intracellular signaling pathways related to autophagy regulation—critical for studying neurodegenerative disease progression mechanisms (Angewandte Chemie International Edition, 2023).

In metabolic engineering applications, derivatives containing this scaffold have been shown to enhance enzyme stability under harsh conditions typical of industrial biocatalysis processes. A study published in *ACS Catalysis* (January 2024) demonstrated up to three-fold increases in catalytic efficiency when used as additives in cellulase systems operating at elevated temperatures—important advancements for biofuel production applications.

Rational drug design efforts using computational methods have identified novel analogs where substituents on the benzoyl ring modulate selectivity between HDAC isoforms while maintaining overall structural integrity. Quantum mechanical calculations revealed that meta-substituted groups significantly alter electrostatic potentials around the imidazole ring without disrupting hydrogen bonding networks—findings now guiding lead optimization campaigns targeting specific disease pathways.

Preclinical toxicity studies conducted under GLP guidelines indicate favorable safety profiles when administered orally or intravenously at therapeutic concentrations. Recent pharmacokinetic data from mouse models show half-life extension through fatty acid ester prodrug strategies without compromising metabolic stability—a critical advancement toward clinical translation published last quarter in *Journal of Pharmacology and Experimental Therapeutics*.

Solid-state NMR analysis revealed polymorphic forms differing primarily by hydrogen bonding configurations between carboxylic acid groups and imidazole nitrogens. Researchers at ETH Zurich identified Form II polymorph exhibiting superior crystallinity and dissolution rates—properties now being optimized through mechanochemical synthesis methods described earlier this year (*Crystal Growth & Design*, March 2024).

In biomaterial science applications, self-assembling peptide analogs incorporating this scaffold demonstrate tunable gelation properties dependent on pH conditions. A recent publication (*Advanced Materials*, July 2023) describes pH-sensitive hydrogels formed through imidazole-carboxylate interactions showing promise as localized drug delivery matrices for ocular diseases requiring sustained release profiles over weeks rather than hours.

Surface plasmon resonance experiments comparing binding kinetics across different isoforms provided mechanistic insights into substrate recognition processes involving this compound’s hybrid functionalities. These studies established a correlation between imidazole protonation states and binding affinity variations across different pH environments—data crucial for designing tissue-specific drug delivery systems targeting acidic tumor microenvironments (*Analytical Chemistry*, October 2023).

X-ray crystallography resolved ternary complexes showing simultaneous inhibition of two distinct enzymatic sites via conformational changes induced by substrate binding—a phenomenon termed "allosteric lock" by researchers at Weill Cornell Medicine (*Structure*, May 2024). This discovery opens new avenues for developing multi-target drugs addressing complex disease mechanisms requiring simultaneous pathway modulation.

• 31373-65-6(Hippuryl-L-histidyl-L-leucine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)